


 Assentio
 Holdings, Inc.


SVB Securities Serves as Financial Advisor to Assentio (NASDAQ: ASRT) on its Pending Acquisition of Spectrum (NASDAQ: SPPI) in an All-Stock and CYR Transaction

Key Transaction Highlights

- On April 26, 2023, Assentio Holdings, Inc. (NASDAQ: ASRT) ("Assentio"), a specialty pharmaceutical company offering differentiated products to patients, and Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) ("Spectrum"), a commercial stage biopharmaceutical company focused on novel and targeted oncology, announced that they have entered into a definitive agreement pursuant to which Assentio will acquire all outstanding shares of Spectrum in an all-stock and contingent value rights ("CYR") transaction
 - Spectrum shareholders will receive either consideration of \$150 ASRT shares per SPPI share plus one CYR warrant from to receive up to an additional \$0.25 per share
 - Following the close of the transaction, Assentio shareholders will own approximately 80% of the combined company and Spectrum shareholders will own approximately 20%, or a fully diluted basis
- In addition to Assentio key assets Intivity, Sympana and Miravos, Spectrum has over \$600M in all-research meaningful future asset development. Assentio offers a long-term growth driver ("GDD") intended to increase the incidence of infection, as facilitated by viral reactivation, in patients with non-muscular xanthomas requiring immunosuppressants and other drugs associated with clinically significant incidence of viral reactivation
- Assentio's derivative split non-secured value model complements Spectrum's robust commercial infrastructure, providing greater market access and resources than either company as a standalone entity
- Transaction is expected to be accretive to Adjusted EPS and Operating Cash Flow in 2024
- The transaction is expected to close in the first quarter of 2023

About Assentio Holdings, Inc.

Assentio is a specialty pharmaceutical company offering differentiated products to patients utilizing a non-secured pharmaceutical model. The company has built and continues to build its commercial portfolio by identifying new opportunities within its existing products as well as acquisitions or licensing of additional approved products.

About Spectrum Pharmaceuticals, Inc.

Spectrum is a commercial stage biopharmaceutical company with a strategy of acquiring, developing, and commercializing novel and targeted oncology therapies. Spectrum has an extensive clinical development organization with regulatory and data management capabilities, in addition to commercial infrastructure and a full-based sales force for its marketed product, ROYALDON™ (afegustamir) oral injection.

For more information, visit www.svb.com. For media inquiries, visit www.svb.com/press.

This press release contains information that may be deemed confidential under applicable securities laws and is being disseminated solely for informational purposes. It is not intended to constitute an offer of securities. This information does not constitute an offer of securities in any state where such offer is prohibited. For more information, visit www.svb.com/press.

 SVB SECURITIES
 1100 Lakeside Drive
 Lake Mary, FL 32746
 Phone: 407-940-1100

 SVB SECURITIES
 4755 North Central
 Phoenix, AZ 85018

 SVB SECURITIES
 40000 Wilshire Blvd
 Encino, CA 91436
 Phone: 818-808-2100

 SVB SECURITIES
 100 Avenue of the Americas
 New York, NY 10038
 Phone: 212-302-2200

 SVB SECURITIES
 80 California Street
 San Francisco, CA 94111
 Phone: 415-774-6000

www.svb.com
www.svb.com